Core Viewpoint - The stock of Pagoda Biopharma-B (02565) opened over 7% higher, reflecting positive market sentiment following the announcement of a lock-up extension by cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. [1] Group 1: Stock Performance - Pagoda Biopharma-B's stock rose by 7.03%, reaching HKD 70, with a trading volume of HKD 770,000 [1]. Group 2: Lock-up Extension - The cornerstone investor has agreed not to reduce their holdings of relevant H-shares from the end of the original lock-up period until December 31, 2025, indicating confidence in the company's future prospects [1]. Group 3: Product Approval and Market Potential - The National Medical Products Administration has approved the new drug application for the company's core product PB-119, which is expected to drive significant revenue growth from 2026 to 2029 due to its clinical advantages in treating T2DM and weight loss [1]. - The DCF valuation suggests substantial upside potential for the company, with PB-119 demonstrating outstanding safety and long-lasting effects, particularly suitable for elderly diabetes patients, positioning it as a best-in-class option [1].
港股异动 | 派格生物医药-B(02565)高开逾7% 基石投资者自愿延长禁售期